Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue suppl 7, Pages vii33-vii40
Publisher
Oxford University Press (OUP)
Online
2012-09-20
DOI
10.1093/annonc/mds224
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- European cancer mortality predictions for the year 2012
- (2012) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies
- (2012) S C Larsson et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine : résultats définitifs de l’étude de phase III 2000–2001de la FFCD et de la SFRO
- (2011) M. Barhoumi et al. Cancer Radiotherapie
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study
- (2011) Richard Zubarik et al. GASTROINTESTINAL ENDOSCOPY
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
- (2010) Uwe Pelzer et al. BMC CANCER
- Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma
- (2010) Raphaël Maréchal et al. CANCER
- Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics
- (2010) E. C. Verna et al. CLINICAL CANCER RESEARCH
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
- (2010) Giuseppe Colucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Biliary Drainage for Cancer of the Head of the Pancreas
- (2010) Niels A. van der Gaag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Redefining resection margin status in pancreatic cancer
- (2010) Caroline S. Verbeke et al. HPB
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- ESPEN Guidelines on Parenteral Nutrition: Non-surgical oncology
- (2009) F. Bozzetti et al. CLINICAL NUTRITION
- Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer
- (2009) Donghui Li JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review
- (2009) Florence Huguet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer
- (2009) Hartwig Riediger et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- (2008) Volker Heinemann et al. BMC CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started